Search
TT 173
go.drugbank.com/drugs/DB17717InvestigationalTT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental
Altropane
go.drugbank.com/drugs/DB04947InvestigationalBoston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and
NasoVAX
go.drugbank.com/drugs/DB15859InvestigationalIt is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells[L16313]. … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).
PSN9301
go.drugbank.com/drugs/DB05001ExperimentalPSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing. … PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes.
Pralatrexate
go.drugbank.com/drugs/DB06813ApprovedInvestigational[A246703] As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate analogs due to the novel target of RFC. … [A246693] Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulated by oncogenes.
Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor.
Pentaglobin
go.drugbank.com/drugs/DB15865InvestigationalPentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations. … [A220173] It is comprised of [immunoglobulin G (IgG)](https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).[L16353]
V24343
go.drugbank.com/drugs/DB05201InvestigationalThe anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Gepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. … Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g.
Lobeline
go.drugbank.com/drugs/DB05137InvestigationalAn alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. … It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]